<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event required):
October 12, 1998
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
- --------------- -------------- ----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eastontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 732-676-1200
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today that, based
on preliminary unaudited data, the Company expects to report a strong profit for
the third quarter ended September 30, 1998. Roberts said it expects
third-quarter 1998 per share earnings to exceed the high end of the First Call
estimate range of $0.10 to $0.13.
Revenues for the three months ended September 30, 1998 are expected to
again exceed the $40 million level. Additionally, the quarterly gross profit
margin should continue to reflect the strength achieved earlier in the year due
to the shift in product mix towards new higher margin pharmaceuticals. Moreover,
Roberts has continued to focus on improving its operating efficiencies and the
Company anticipates a meaningful decline in third-quarter selling,
administrative and general expenses as a percent of revenues.
Roberts further noted that its optimistic outlook for third-quarter
profits is based on a strong operating performance. The Company stated that
third quarter results would be reported during the week of October 19, 1998.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: October 13, 1998 By: /s/ Anthony A. Rascio
------------------------------
Anthony A. Rascio
Vice President
<PAGE>
-3-
FORWARD LOOKING STATEMENTS
Certain statements included in Item 5 of this form 8-K are intended to
be, and are hereby identified as, forward looking statements for purposes of the
safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as
amended, and Section 27A of the Securities Act of 1933, as amended. The
Registrant cautions readers that forward looking statements, including, without
limitation, those relating to the Registrant's future business prospects,
revenues, cost of sales, intangible dispositions and write-offs, continuing
operations and discontinued operations, and liquidity and capital resources, are
subject to certain risks and uncertainties, including, without limitation, the
ability of the Registrant to secure regulatory approval in the United States and
in foreign jurisdictions for the Registrant's developmental pipeline drugs, the
effort of the Registrant's competitors and the introduction of rival
pharmaceutical products which may prove to be more effective than the
Registrant's products, general market conditions, the availability of capital,
and the uncertainty over the future direction of the healthcare industry, that
could cause actual results to differ materially from those indicated in the
forward looking statements.
